Rhythm Pharmaceuticals (NASDAQ:RYTM) vs. Janux Therapeutics (NASDAQ:JANX) Financial Comparison

Janux Therapeutics (NASDAQ:JANX) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, valuation, institutional ownership, risk and dividends.

Institutional & Insider Ownership

75.4% of Janux Therapeutics shares are held by institutional investors. 7.9% of Janux Therapeutics shares are held by insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Janux Therapeutics and Rhythm Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$24.00 million	42.99	-$113.62 million	($1.64)	-10.29
Rhythm Pharmaceuticals	$189.76 million	38.34	-$196.54 million	($2.90)	-36.18

Janux Therapeutics has higher earnings, but lower revenue than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for Janux Therapeutics and Rhythm Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2	2	10	1	2.67
Rhythm Pharmaceuticals	1	3	18	0	2.77

Janux Therapeutics presently has a consensus target price of $36.46, suggesting a potential upside of 116.03%. Rhythm Pharmaceuticals has a consensus target price of $142.17, suggesting a potential upside of 35.48%. Given Janux Therapeutics’ higher probable upside, analysts clearly believe Janux Therapeutics is more favorable than Rhythm Pharmaceuticals.

Volatility and Risk

Janux Therapeutics has a beta of 2.44, suggesting that its share price is 144% more volatile than the S&P 500. Comparatively, Rhythm Pharmaceuticals has a beta of 2.17, suggesting that its share price is 117% more volatile than the S&P 500.

Profitability

This table compares Janux Therapeutics and Rhythm Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-11.89%	-11.13%
Rhythm Pharmaceuticals	-69.03%	-171.16%	-43.00%

Summary

Janux Therapeutics beats Rhythm Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

About Janux Therapeutics

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.